Doublet Chemotherapy Plus EGFR/BRAF Targeting Yields Best Survival in Advanced BRAF‑Mutated Colorectal Cancer: A 4,633‑Patient Network Meta‑Analysis

Highlights

– Network meta‑analysis of 60 studies with 4,633 patients supports anti‑EGFR/BRAF combinations as the therapeutic backbone for advanced BRAF‑mutated colorectal cancer (mCRC).

– In first‑line treatment, doublet chemotherapy plus anti‑EGFR/BRAF (the “doublet‑double‑target” approach) produced the largest overall survival benefit (HR vs DCT‑anti‑VEGF 0.49, 95% CrI 0.36–0.66).